About
Dr. Matthew Boente MD is a physician with many years of experience in the field of Obstetrics and Gynecology, with a subspecialty in Gynecologic Oncology. Dr. Boente has had academic administrative appointments in different medical institutions such as Fox Chase Cancer Center, Methodist Hospital, University of Minnesota, and Minneapolis CCOP.
Through the years, Dr. Matthew Boente MD has received numerous awards for his work and contribution to the medical field. Dr. Boente was among the recipients of the Top Doctor Award given by Minneapolis-St. Paul Magazine and Minnesota Monthly’s Best Doctors for Women. In 2012, he received the National Cancer Institute Gold Certificate of Excellence Award.
Dr. Matthew Boente MD has served as a member of the Board of Directors of Minnesota Ovarian Cancer Alliance, Minnesota Oncology, and Blake School Hockey Association. He also received several academic administrative appointments, including as Principal Investigator at Minnesota Oncology. During his stint as Medical Director for U.S. Medical Affairs, Gyn-Oncology at Genentech Inc. in San Francisco, Dr. Boente led a large global cross-functional team responsible for the FDA approval of bevacizumab with chemotherapy in front line ovarian cancer. He holds memberships in professional societies, including the American Medical Association, American Association for Cancer Research, American College of Obstetrics and Gynecology, American College of Surgeons, and American Society of Clinical Oncology.
Through the years, Dr. Matthew Boente MD has received numerous awards for his work and contribution to the medical field. Dr. Boente was among the recipients of the Top Doctor Award given by Minneapolis-St. Paul Magazine and Minnesota Monthly’s Best Doctors for Women. In 2012, he received the National Cancer Institute Gold Certificate of Excellence Award.
Dr. Matthew Boente MD has served as a member of the Board of Directors of Minnesota Ovarian Cancer Alliance, Minnesota Oncology, and Blake School Hockey Association. He also received several academic administrative appointments, including as Principal Investigator at Minnesota Oncology. During his stint as Medical Director for U.S. Medical Affairs, Gyn-Oncology at Genentech Inc. in San Francisco, Dr. Boente led a large global cross-functional team responsible for the FDA approval of bevacizumab with chemotherapy in front line ovarian cancer. He holds memberships in professional societies, including the American Medical Association, American Association for Cancer Research, American College of Obstetrics and Gynecology, American College of Surgeons, and American Society of Clinical Oncology.
Comments
Post a Comment